Replies to post #206688 on Biotech Values

[Whalatane]

PRTO re B.AVF vs R .AVF

Poorgrad ..I'm not an MD so if I have this wrong please correct.

Their ( wifes' renal dept ) central point is that their B AVF patients often have more severe commorbities , have been on dialysis longer , and have exhausted their R AVF options .....ie they aren't the same populations.
Their ( from memory ) B AVF's use the basillic vein where as their R AVF's use the cephalic vein

The difference between basillic and other veins including the cephalic vein include the following ...from Proteon literature

"elastin removal with vonapanitase treatment was generally similar when expressed as a percentage reduction, with the exception being that of the basilic vein where at a dose of 1 mg/mL only 30% of elastin (desmosine) was removed after 15 min versus 61–72% for the other vein types. "

So ...a 30 ug dose applied to a "sicker " patient with a B AVF using the basiliac vein will not be the same as a 30ug dose applied to a "healthier " patient getting their first R AVF using their cephalic vein.

PATENCY 1 is 30ug dose applied to R.AVF ( cephalic vein ) in a patients first AVF.
This is the population they believe will benefit the most ...if it works.

Kiwi